3[1]McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha - 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].N EngJ Med, 1998, 339:1485- 1492.
4[2]Saracco G, Borghesio E, Mesina P, etal. Prolonged treatment (2 years)with different doses (3 versus 6 MU) of interferon alpha- 2b for chronic hepatitis C. Results of a multicenter randomized trial [J]. J Hepatol,1997, 27:56-62.
5[3]Roberts MJ, Harris JM. Attachment of degradable poly (ethylene glycol)to proteins has the potential to increase therapeutic efficacy[J]. J Pharm Sci, 1998, 87:1440- 1445.
6[4]Zeuzem S. Clinical implications of hepatitis C viral kinetics[J].J Hepatol, 1999, 31(Suppll):61-64.
7[5]Neumann AU, Lam NP, Dahari H, etal. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon - α therapy [J]. Science,1998, 282:103 - 107.
8[6]Monkarsh SP, Ma Y, Aglione A, etal. Positional isomers of monopegy-lated interferon alpha -2a: isolation, characterization, and biological ac-tivity[J].Anal Biochem, 1997, 247:434-440.
9[7]Zeuzam S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a[J].Gastroenterology, 2001, 120:1438 - 1447.
10[8]Reddy KR, Wright TL, Pockros PJ, etal. Efficacy and safety of pegylated (40- kd) interferon alpha- 2a compared with interferon alpha- 2a in noncirrhotc patients with chronic hepatitis C[J].Hepatolgy, 2001, 33:433 - 438.
